Literature DB >> 22226279

What can we learn from patient-reported outcomes of insulin pen devices?

Barbara J Anderson1, Maria J Redondo.   

Abstract

Although a variety of effective treatment options are available for patients with type 1 or type 2 diabetes, many patients in the United States have difficulty reaching their glycemic goals. Patient adherence to insulin therapy, which often involves self-administered subcutaneous injections of insulin using either a vial and syringe or an insulin pen device, is often poor. Various factors associated with the type of injection device have been shown to influence the rate of patient adherence to insulin therapy. This article reviews patient-reported outcome (PRO) evidence from pediatric and adult studies that compared insulin pen devices with vial and syringe use. In a majority of these cases, patients preferred the pen devices over vial and syringe, stating advantages such as ease of use, convenience, greater confidence in their ability to properly administer the drug, and a greater perceived social acceptance. The pens were considered less painful than syringes and were associated with less needle fear. In addition, PRO evidence has directed pen technology design, leading to development of more advanced insulin pen devices. By appreciating the correlation between adherence to insulin regimens and a patient's device preference, clinicians can make improved treatment recommendations to facilitate achievement and maintenance of glycemic targets.
© 2011 Diabetes Technology Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22226279      PMCID: PMC3262728          DOI: 10.1177/193229681100500633

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN: 1932-2968


  69 in total

Review 1.  Care of children and adolescents with type 1 diabetes: a statement of the American Diabetes Association.

Authors:  Janet Silverstein; Georgeanna Klingensmith; Kenneth Copeland; Leslie Plotnick; Francine Kaufman; Lori Laffel; Larry Deeb; Margaret Grey; Barbara Anderson; Lea Ann Holzmeister; Nathaniel Clark
Journal:  Diabetes Care       Date:  2005-01       Impact factor: 19.112

2.  Is glycemic control improving in U.S. adults?

Authors:  Thomas J Hoerger; Joel E Segel; Edward W Gregg; Jinan B Saaddine
Journal:  Diabetes Care       Date:  2007-10-12       Impact factor: 19.112

3.  Quality of life as a key indicator of patient satisfaction and treatment compliance in people with type 2 diabetes mellitus in the IMPROVE study: a multicentre, open label, non-randomised, observational trial.

Authors:  Apurba Kumar Mukherjee; Vijay Shekar Reddy; Siddharth Shah; A K Jhingan; P Ramakrishnan; Vinay Prusty; Naorem Santa Singh
Journal:  J Indian Med Assoc       Date:  2009-07

4.  A comparison of injection force and dosage scale size between NovoPen 3 and NovoPen 4.

Authors:  Morten Donsmark; Lars Herold; Carsten Mølgård Kristensen
Journal:  Diabetes Technol Ther       Date:  2009-09       Impact factor: 6.118

Review 5.  Assessment of patient-reported outcomes of insulin pen devices versus conventional vial and syringe.

Authors:  Cliff Molife; Lauren J Lee; Lizheng Shi; Monika Sawhney; Sheila M Lenox
Journal:  Diabetes Technol Ther       Date:  2009-08       Impact factor: 6.118

Review 6.  Inadequate pain management during routine childhood immunizations: the nerve of it.

Authors:  Anna Taddio; Christine T Chambers; Scott A Halperin; Moshe Ipp; Donna Lockett; Michael J Rieder; Vibhuti Shah
Journal:  Clin Ther       Date:  2009       Impact factor: 3.393

7.  Patient perceptions of injection pain and anxiety: a comparison of NovoFine 32-gauge tip 6mm and Micro Fine Plus 31-gauge 5mm needles.

Authors:  Midori Iwanaga; Kyuzi Kamoi
Journal:  Diabetes Technol Ther       Date:  2009-02       Impact factor: 6.118

8.  Pen injector for insulin-requiring diabetic patients.

Authors:  C T Hung; F F Wang
Journal:  J Formos Med Assoc       Date:  1992-10       Impact factor: 3.282

9.  Clinical experience with a new device that will simplify insulin injections.

Authors:  A S Berger; N Saurbrey; C Kühl; J Villumsen
Journal:  Diabetes Care       Date:  1985 Jan-Feb       Impact factor: 19.112

10.  A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus.

Authors:  Mary Korytkowski; David Bell; Carol Jacobsen; Rudee Suwannasari
Journal:  Clin Ther       Date:  2003-11       Impact factor: 3.393

View more
  16 in total

1.  Analysis of comparison of patient preference for two insulin injection pen devices in relation to patient dexterity skills.

Authors:  Kellie J Antinori-Lent
Journal:  J Diabetes Sci Technol       Date:  2012-07-01

2.  Practical Guidance on Effective Basal Insulin Titration for Primary Care Providers.

Authors:  Louis Kuritzky; Timothy S Reid; Carol H Wysham
Journal:  Clin Diabetes       Date:  2019-10

3.  Usability of the Gla-300 Injection Device Compared With Three Other Commercialized Disposable Insulin Pens: Results of an Interview-Based Survey.

Authors:  David Klonoff; Irina Nayberg; Frank Erbstein; Anna Cali; Claire Brulle-Wohlhueter; Thomas Haak
Journal:  J Diabetes Sci Technol       Date:  2015-05-22

Review 4.  Identifying and meeting the challenges of insulin therapy in type 2 diabetes.

Authors:  Christopher Sorli; Michael K Heile
Journal:  J Multidiscip Healthc       Date:  2014-07-02

5.  Accuracy and Injection Force of the Gla-300 Injection Device Compared With Other Commercialized Disposable Insulin Pens.

Authors:  David Klonoff; Irina Nayberg; Marissa Thonius; Florian See; Mona Abdel-Tawab; Frank Erbstein; Thomas Haak
Journal:  J Diabetes Sci Technol       Date:  2015-08-26

Review 6.  Challenges and unmet needs in basal insulin therapy: lessons from the Asian experience.

Authors:  Wing Bun Chan; Jung Fu Chen; Su-Yen Goh; Thi Thanh Huyen Vu; Iris Thiele Isip-Tan; Sony Wibisono Mudjanarko; Shailendra Bajpai; Maria Aileen Mabunay; Pongamorn Bunnag
Journal:  Diabetes Metab Syndr Obes       Date:  2017-12-15       Impact factor: 3.168

7.  Using Patient Feedback to Optimize the Design of a Certolizumab Pegol Electromechanical Self-Injection Device: Insights from Human Factors Studies.

Authors:  Barbara Domańska; Oliver Stumpp; Steven Poon; Serkan Oray; Irina Mountian; Clovis Pichon
Journal:  Adv Ther       Date:  2017-12-08       Impact factor: 3.845

8.  The INITIATOR study: pilot data on real-world clinical and economic outcomes in US patients with type 2 diabetes initiating injectable therapy.

Authors:  Sarah Thayer; Wenhui Wei; Erin Buysman; Lee Brekke; William Crown; Michael Grabner; Swetha Raparla; Ralph Quimbo; Mark J Cziraky; Wenli Hu; Robert Cuddihy
Journal:  Adv Ther       Date:  2013-11-30       Impact factor: 3.845

9.  Initial experience and evaluation of reusable insulin pen devices among patients with diabetes in emerging countries.

Authors:  Balduino Tschiedel; Oscar Almeida; Jennifer Redfearn; Frank Flacke
Journal:  Diabetes Ther       Date:  2014-09-12       Impact factor: 2.945

Review 10.  A Systematic Review of Patients' Perspectives on the Subcutaneous Route of Medication Administration.

Authors:  Colin H Ridyard; Dalia M M Dawoud; Lorna V Tuersley; Dyfrig A Hughes
Journal:  Patient       Date:  2016-08       Impact factor: 3.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.